Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 40.9% in March

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 70,800 shares, a decrease of 40.9% from the February 28th total of 119,700 shares. Based on an average trading volume of 1,850,000 shares, the short-interest ratio is currently 0.0 days. Currently, 3.9% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC purchased a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.39% of Cyclerion Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Price Performance

NASDAQ:CYCN traded down $0.04 during trading hours on Friday, hitting $2.57. The stock had a trading volume of 12,682 shares, compared to its average volume of 1,321,396. The company has a 50 day simple moving average of $2.95 and a two-hundred day simple moving average of $2.89. The firm has a market capitalization of $6.96 million, a price-to-earnings ratio of -2.11 and a beta of 2.09. Cyclerion Therapeutics has a one year low of $1.27 and a one year high of $9.47.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $1.81 million for the quarter.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.